These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23086559)

  • 1. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.
    Roscioni SS; de Zeeuw D; Hellemons ME; Mischak H; Zürbig P; Bakker SJ; Gansevoort RT; Reinhard H; Persson F; Lajer M; Rossing P; Lambers Heerspink HJ
    Diabetologia; 2013 Feb; 56(2):259-67. PubMed ID: 23086559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes.
    Pena MJ; Jankowski J; Heinze G; Kohl M; Heinzel A; Bakker SJ; Gansevoort RT; Rossing P; de Zeeuw D; Heerspink HJ; Jankowski V
    J Hypertens; 2015 Oct; 33(10):2123-32. PubMed ID: 26237555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
    Lindhardt M; Persson F; Zürbig P; Stalmach A; Mischak H; de Zeeuw D; Lambers Heerspink H; Klein R; Orchard T; Porta M; Fuller J; Bilous R; Chaturvedi N; Parving HH; Rossing P
    Nephrol Dial Transplant; 2017 Nov; 32(11):1866-1873. PubMed ID: 27507891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus.
    Pena MJ; Lambers Heerspink HJ; Hellemons ME; Friedrich T; Dallmann G; Lajer M; Bakker SJ; Gansevoort RT; Rossing P; de Zeeuw D; Roscioni SS
    Diabet Med; 2014 Sep; 31(9):1138-47. PubMed ID: 24661264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case-control study with confirmation in diabetes.
    Hellemons ME; Lambers Heerspink HJ; Gansevoort RT; de Zeeuw D; Bakker SJ
    J Hypertens; 2013 Apr; 31(4):805-12. PubMed ID: 23425705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria.
    Oellgaard J; Gæde P; Persson F; Rossing P; Parving HH; Pedersen O
    J Diabetes Complications; 2018 Dec; 32(12):1133-1140. PubMed ID: 30282584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
    Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
    Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria.
    Currie GE; von Scholten BJ; Mary S; Flores Guerrero JL; Lindhardt M; Reinhard H; Jacobsen PK; Mullen W; Parving HH; Mischak H; Rossing P; Delles C
    Cardiovasc Diabetol; 2018 Apr; 17(1):50. PubMed ID: 29625564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes.
    Jørgensen PG; Biering-Sørensen T; Mogelvang R; Fritz-Hansen T; Vilsbøll T; Rossing P; Jensen JS
    Eur Heart J Cardiovasc Imaging; 2018 Sep; 19(9):1034-1041. PubMed ID: 29029007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Podocyturia parallels proximal tubule dysfunction in type 2 diabetes mellitus patients independently of albuminuria and renal function decline: A cross-sectional study.
    Petrica L; Vlad M; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Popescu R; Gluhovschi C; Matusz P; Velciov S; Bob F; Ursoniu S; Vlad D
    J Diabetes Complications; 2017 Sep; 31(9):1444-1450. PubMed ID: 28161386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes.
    Hellemons ME; Mazagova M; Gansevoort RT; Henning RH; de Zeeuw D; Bakker SJ; Lambers-Heerspink HJ; Deelman LE
    Diabetes Care; 2012 Nov; 35(11):2340-6. PubMed ID: 22815297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT).
    Kern EF; Erhard P; Sun W; Genuth S; Weiss MF
    Am J Kidney Dis; 2010 May; 55(5):824-34. PubMed ID: 20138413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria.
    von Scholten BJ; Reinhard H; Hansen TW; Oellgaard J; Parving HH; Jacobsen PK; Rossing P
    Diabetologia; 2016 Jul; 59(7):1549-1557. PubMed ID: 27033561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression.
    Critselis E; Lambers Heerspink H
    Nephrol Dial Transplant; 2016 Feb; 31(2):249-54. PubMed ID: 25791724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary podocyte mRNAs precede microalbuminuria as a progression risk marker in human type 2 diabetic nephropathy.
    Fukuda A; Minakawa A; Kikuchi M; Sato Y; Nagatomo M; Nakamura S; Mizoguchi T; Fukunaga N; Shibata H; Naik AS; Wiggins RC; Fujimoto S
    Sci Rep; 2020 Oct; 10(1):18209. PubMed ID: 33097787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary heme oxygenase-1 as a potential biomarker for early diabetic nephropathy.
    Li Z; Xu Y; Liu X; Nie Y; Zhao Z
    Nephrology (Carlton); 2017 Jan; 22(1):58-64. PubMed ID: 26733347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microalbuminuria and macroalbuminuria in type 2 diabetes.
    Maharjan BR; Bhandary S; Risal P; Sedhain A; Shakya PR; Gautam M
    J Nepal Health Res Counc; 2010 Oct; 8(2):110-5. PubMed ID: 21876575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.
    Lindhardt M; Persson F; Oxlund C; Jacobsen IA; Zürbig P; Mischak H; Rossing P; Heerspink HJL
    Nephrol Dial Transplant; 2018 Feb; 33(2):296-303. PubMed ID: 28064163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes.
    Schlatzer D; Maahs DM; Chance MR; Dazard JE; Li X; Hazlett F; Rewers M; Snell-Bergeon JK
    Diabetes Care; 2012 Mar; 35(3):549-55. PubMed ID: 22238279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.